Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 3, Pages 1665
Publisher
MDPI AG
Online
2022-02-01
DOI
10.3390/ijms23031665
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype
- (2021) Audree B. Tadros et al. ANNALS OF SURGICAL ONCOLOGY
- ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc
- (2021) Yuanyuan Cheng et al. Cancer Cell International
- Ceramide kinase mediates intrinsic resistance and inferior response to chemotherapy in triple‐negative breast cancer by upregulating Ras/ERK and PI3K/Akt pathways
- (2021) Shan Zhu et al. Cancer Cell International
- Single-cell long noncoding RNA (lncRNA) transcriptome implicates MALAT1 in triple-negative breast cancer (TNBC) resistance to neoadjuvant chemotherapy
- (2021) Hibah Shaath et al. Cell Death Discovery
- Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer
- (2021) Yinqi Gao et al. MEDICAL SCIENCE MONITOR
- Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
- (2021) Rebecca Dent et al. BREAST CANCER RESEARCH AND TREATMENT
- Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer
- (2021) Jing Chen et al. Annals of Translational Medicine
- Investigational Drug Treatments for Triple-Negative Breast Cancer
- (2021) Christos Damaskos et al. Journal of Personalized Medicine
- Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies
- (2021) Evanthia T. Roussos Torres et al. BREAST CANCER RESEARCH AND TREATMENT
- Noncoding RNAs in triple negative breast cancer: Mechanisms for chemoresistance
- (2021) Min Xia et al. CANCER LETTERS
- Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
- (2021) Timothee Olivier et al. Translational Oncology
- Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2021) Braydon Meyer et al. Clinical Epigenetics
- Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
- (2021) Jigang Chen et al. Frontiers in Oncology
- Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
- (2020) Po‐Han Lin et al. CANCER SCIENCE
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application
- (2020) Le Zhang et al. Molecular Cancer
- BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
- (2020) Yoshimasa Kosaka et al. Diagnostics
- Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study
- (2020) Ruo-Xi Wang et al. BREAST CANCER RESEARCH AND TREATMENT
- Neoadjuvant or adjuvant chemotherapy in early breast cancer?
- (2020) Filippo Montemurro et al. EXPERT OPINION ON PHARMACOTHERAPY
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway
- (2020) Qiao Zheng et al. BIOSCIENCE REPORTS
- TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer
- (2020) Hui-Yu Lin et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines
- (2020) Saeko Teraoka et al. JOURNAL OF SURGICAL RESEARCH
- Association between the methylation status of PCDH17 and the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer
- (2020) De-Di Kong et al. Oncology Letters
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
- (2020) P.A. Fasching et al. ANNALS OF ONCOLOGY
- Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1
- (2020) Emarene Kalaw et al. BRITISH JOURNAL OF CANCER
- CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis
- (2020) Dongwei Dou et al. Cancer Cell International
- Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer
- (2020) Piotr Przanowski et al. CANCER RESEARCH
- Metaplastic breast cancer: Prognostic and therapeutic considerations
- (2020) Giovanni Corso et al. JOURNAL OF SURGICAL ONCOLOGY
- The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy
- (2020) Andrew S. Murray et al. ONCOGENE
- Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA
- (2020) Qian Zhang et al. ONCOLOGY REPORTS
- Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer
- (2020) Bruna Cerbelli et al. Cancers
- Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer
- (2020) Xiangmei Zhang et al. Annals of Translational Medicine
- PITX2 DNA-Methylation: Predictive versus Prognostic Value for Anthracycline-Based Chemotherapy in Triple-Negative Breast Cancer Patients
- (2020) Rudolf Napieralski et al. Breast Care
- Triple-negative breast cancer: promising prognostic biomarkers currently in development
- (2020) Jasmine Sukumar et al. Expert Review of Anticancer Therapy
- BRCAness as a prognostic indicator in patients with early breast cancer
- (2020) Lei Liu et al. Scientific Reports
- Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
- (2020) H.P. Eikesdal et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients
- (2019) Ryungsa Kim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor
- (2019) Kamal Ahmed et al. CANCER LETTERS
- Secretory Carcinoma of the Breast: Clinicopathologic Profile of 14 Cases Emphasizing Distant Metastatic Potential
- (2019) Raza S. Hoda et al. HISTOPATHOLOGY
- AL101 mediated tumor inhibition in notch-altered TNBC PDX models.
- (2019) Esther Channah Broner et al. JOURNAL OF CLINICAL ONCOLOGY
- STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
- (2019) Jiang-Jiang Qin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2
- (2019) Zhenyuan Gao et al. PATHOLOGY RESEARCH AND PRACTICE
- Overexpression of microRNA‑620 facilitates the resistance of triple negative breast cancer cells to gemcitabine treatment by targeting DCTD
- (2019) Chao Wu et al. Experimental and Therapeutic Medicine
- Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly
- (2019) Pia Giovannelli et al. Scientific Reports
- Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer
- (2019) Masahiro Shibata et al. Cancers
- MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2
- (2019) Mei Liu et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin
- (2019) Honghong Shen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- (2019) Jennifer K. Litton et al. JOURNAL OF CLINICAL ONCOLOGY
- The Hedgehog Signaling Pathway: A Viable Target in Breast Cancer?
- (2019) Priyanka Bhateja et al. Cancers
- WNT Signaling in Disease
- (2019) Ng et al. Cells
- Triple negative breast cancer: A thorough review of biomarkers
- (2019) Jesse Lopes da Silva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- PI3K Inhibitors in Breast Cancer Therapy
- (2019) Haley Ellis et al. Current Oncology Reports
- TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis
- (2018) Xiaodan Xu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo
- (2018) Guan-Nan Zhang et al. CANCER LETTERS
- Abstract P2-09-15:NTRKfusions in breast cancer: Clinical, pathologic and genomic findings
- (2018) JS Ross et al. CANCER RESEARCH
- Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
- (2018) Isabel Echavarria et al. CLINICAL CANCER RESEARCH
- Advances in the systemic treatment of triple-negative breast cancer
- (2018) J.M. Lebert et al. Current Oncology
- STAT3 as a promising chemoresistance biomarker associated with the CD44 +/high /CD24 -/low /ALDH + BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line
- (2018) Milene Pereira Moreira et al. EXPERIMENTAL CELL RESEARCH
- STAT3: a multifaceted oncoprotein
- (2018) Aleks C. Guanizo et al. GROWTH FACTORS
- Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer
- (2018) Abhishek Gangrade et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- MicroRNAs in regulation of triple-negative breast cancer progression
- (2018) Dominika Piasecka et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
- (2018) Tiffany A. Traina et al. JOURNAL OF CLINICAL ONCOLOGY
- Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
- (2018) Ellen R Copson et al. LANCET ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- miRNAs as Potential Treatment Targets and Treatment Options in Cancer
- (2018) Nina Petrovic et al. Molecular Diagnosis & Therapy
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer
- (2018) Sherona R. Sirkisoon et al. ONCOGENE
- Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment
- (2018) Garcia-Chagollan Mariel et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1
- (2018) Yaming Li et al. Cell Death & Disease
- MCL-1 is a prognostic indicator and drug target in breast cancer
- (2018) Kirsteen J. Campbell et al. Cell Death & Disease
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
- (2018) Naoko Matsuda et al. JAMA Oncology
- A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway
- (2018) Wei Xie et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial
- (2018) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy
- (2018) Yi-Hui Li et al. MEDICINE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- The inhibitory effects of plumbagin on the NF-қB pathway and CCL2 release in racially different triple-negative breast cancer cells
- (2018) Samia S. Messeha et al. PLoS One
- MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer
- (2018) Mustafa Kahraman et al. Scientific Reports
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
- (2018) Fouzia Guestini et al. BREAST CANCER RESEARCH AND TREATMENT
- Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer
- (2018) Wenlong Li et al. ONCOLOGY REPORTS
- miR‑1207‑5p regulates the sensitivity of triple‑negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression
- (2018) Xiaoke Hou et al. Oncology Letters
- Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
- (2018) Yen-Dun Tony Tzeng et al. Frontiers in Pharmacology
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC)
- (2017) Fei Ma et al. MEDICINE
- Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas
- (2017) Gregor Krings et al. MODERN PATHOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells
- (2017) Yoshikazu Koike et al. Breast Cancer
- Co‑activation of Hedgehog and Wnt signaling pathways is associated with poor outcomes in triple negative breast cancer
- (2017) Kimberly Arnold et al. Oncology Letters
- Function of insulin‑like growth factor 1 receptor in cancer resistance to chemotherapy (Review)
- (2017) Jingsheng Yuan et al. Oncology Letters
- CD44+/CD24‑ phenotype predicts a poor prognosis in triple‑negative breast cancer
- (2017) Hui Wang et al. Oncology Letters
- STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer
- (2017) Wei-Ying Kuo et al. Theranostics
- The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
- (2017) Viriya Kaewkangsadan et al. Journal of Immunology Research
- STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line
- (2017) Hoda Soleymani Abyaneh et al. Cancers
- A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)
- (2016) H. Bonnefoi et al. ANNALS OF ONCOLOGY
- Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base
- (2016) John Doromal Jacob et al. JOURNAL OF SURGICAL ONCOLOGY
- Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
- (2016) S Chouaib et al. ONCOGENE
- Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer
- (2016) Marzia A. Locatelli et al. Oncotarget
- Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
- (2016) Abderrahim El Guerrab et al. Oncotarget
- Hypoxia Induced NF-κB
- (2016) Laura D’Ignazio et al. Cells
- Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
- (2016) Brian D. Lehmann et al. PLoS One
- Polymer Nanoparticles Mediated Codelivery of AntimiR-10b and AntimiR-21 for Achieving Triple Negative Breast Cancer Therapy
- (2015) Rammohan Devulapally et al. ACS Nano
- Tumor suppressive functions of ceramide: evidence and mechanisms
- (2015) Sehamuddin Galadari et al. APOPTOSIS
- Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy
- (2015) Baek Kim et al. BMC CANCER
- Clinical implications of molecular heterogeneity in triple negative breast cancer
- (2015) Brian D. Lehmann et al. BREAST
- Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
- (2015) Virginia G. Kaklamani et al. BREAST CANCER RESEARCH AND TREATMENT
- A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
- (2015) S Cowherd et al. CANCER BIOLOGY & THERAPY
- Wnt/ -Catenin Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-like Cells
- (2015) G.-B. Jang et al. CANCER RESEARCH
- TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
- (2015) A. Forero-Torres et al. CLINICAL CANCER RESEARCH
- The wound inflammatory response exacerbates growth of pre-neoplastic cells and progression to cancer
- (2015) N. Antonio et al. EMBO JOURNAL
- A Time to Kill: Targeting Apoptosis in Cancer
- (2015) Jean Koff et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery
- (2015) Chandan Verma et al. Journal of Translational Medicine
- Targeting the TGFβ pathway for cancer therapy
- (2015) Cindy Neuzillet et al. PHARMACOLOGY & THERAPEUTICS
- Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer
- (2015) Yingqian Lv et al. OncoTargets and Therapy
- Epigenetic changes and nuclear factor-κB activation, but not microRNA-224, downregulate Raf-1 kinase inhibitor protein in triple-negative breast cancer SUM 159 cells
- (2015) MANUELA LABBOZZETTA et al. Oncology Letters
- FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-like Breast Cancer
- (2015) Bingchen Han et al. Cell Reports
- Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation
- (2015) Susan M. Farabaugh et al. Frontiers in Endocrinology
- β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells
- (2015) Jinhua Xu et al. PLoS One
- Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients
- (2015) Sandra Heskamp et al. PLoS One
- Quantitative network mapping of the human kinome interactome reveals new clues for rational kinase inhibitor discovery and individualized cancer therapy
- (2015) Feixiong Cheng et al. Oncotarget
- Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
- (2014) J. M. Nabholtz et al. ANNALS OF ONCOLOGY
- Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC)
- (2014) Fei Ma et al. CANCER LETTERS
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2014) J. R. Brown et al. CLINICAL CANCER RESEARCH
- The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib
- (2014) Letizia Porcelli et al. CURRENT DRUG TARGETS
- High EGFR gene copy number predicts poor outcome in triple-negative breast cancer
- (2014) Heae Surng Park et al. MODERN PATHOLOGY
- Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy
- (2014) Jennifer Sims-Mourtada et al. MOLECULAR CARCINOGENESIS
- Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
- (2014) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- STAT3 Signaling Is Activated Preferentially in Tumor-Initiating Cells in Claudin-Low Models of Human Breast Cancer
- (2014) Wei Wei et al. STEM CELLS
- Wnt signaling in triple negative breast cancer is associated with metastasis
- (2013) Nandini Dey et al. BMC CANCER
- High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival
- (2013) Akimitsu Yamada et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8
- (2013) Z. C. Hartman et al. CANCER RESEARCH
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Nonclassical Activation of Hedgehog Signaling Enhances Multidrug Resistance and Makes Cancer Cells Refractory to Smoothened-targeting Hedgehog Inhibition
- (2013) Shamik Das et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
- (2013) Neil E. Bhola et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
- (2013) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients
- (2013) Maria Ascierto et al. Journal of Translational Medicine
- Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer
- (2013) S. Yin et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
- (2013) A. Prat et al. ONCOLOGIST
- Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
- (2013) J. M. Balko et al. Cancer Discovery
- Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
- (2012) Jean-Philippe Cosse et al. Anti-Cancer Agents in Medicinal Chemistry
- Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients
- (2012) Naofumi Oda et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
- (2012) L. Malorni et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of epidermal growth factor receptor in breast cancer
- (2012) Hiroko Masuda et al. BREAST CANCER RESEARCH AND TREATMENT
- Breast cancer, side population cells and ABCG2 expression
- (2012) K.M. Britton et al. CANCER LETTERS
- Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells
- (2012) Ming Qiu et al. CANCER LETTERS
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Molecular Pathways: Targeting the TGF- Pathway for Cancer Therapy
- (2012) A. L. Smith et al. CLINICAL CANCER RESEARCH
- Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma
- (2012) Lei Xiang et al. Diagnostic Pathology
- Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-κB activity via the Notch-1 pathway
- (2012) HONG PAN et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics
- (2012) Shaomeng Wang et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer
- (2012) Hiroki Nakajima et al. Breast Cancer
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
- (2011) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer
- (2011) H E Lee et al. BRITISH JOURNAL OF CANCER
- TGF /TNF -Mediated Epithelial-Mesenchymal Transition Generates Breast Cancer Stem Cells with a Claudin-Low Phenotype
- (2011) M. K. Asiedu et al. CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- (2011) Ingrid E. Wertz et al. NATURE
- Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61
- (2011) L G Harris et al. ONCOGENE
- Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
- (2010) H. Harrison et al. CANCER RESEARCH
- Ceramide kinase: The first decade
- (2010) Frédéric Bornancin CELLULAR SIGNALLING
- Heterogeneity for Stem Cell-Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer
- (2010) S. Y. Park et al. CLINICAL CANCER RESEARCH
- Metastatic Behavior of Breast Cancer Subtypes
- (2010) Hagen Kennecke et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
- (2009) E Y Tan et al. BRITISH JOURNAL OF CANCER
- Pharmacogenetics of Membrane Transporters: An Update on Current Approaches
- (2009) Tristan M. Sissung et al. MOLECULAR BIOTECHNOLOGY
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum
- (2008) Marick Laé et al. MODERN PATHOLOGY
- Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors
- (2008) L S Steelman et al. ONCOGENE
- Hypoxia and Aggressive Tumor Phenotype: Implications for Therapy and Prognosis
- (2008) P. Vaupel ONCOLOGIST
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started